Navigation Links
DURECT Corporation Announces Third Quarter 2010 Financial Results

m clinical trials for our drug candidates, our failure to achieve the performance milestones or commercial sales that trigger the referenced payments or royalties under our collaborative agreements, our (and that of our third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to development activities and products, design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced drug candidates, consummate collaborative agreements relating to our drug candidates and technologies, manufacture and commercialize the referenced drug candidates, obtain marketplace acceptance of the referenced drug candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q on August 5, 2010 under the heading "Risk Factors."DURECT CORPORATIONSTATEMENT OF OPERATIONS DATA(in thousands, except per share amounts)(Unaudited)Three months ended Nine months ended September 30, September 30, 2010200920102009Collaborative research and development and other revenue

9,545Product revenue, net

2,4275,3518,93310,037Total revenues

8,1168,37823,09519,582Operating expenses:Cost of product revenues (1)

8592,8343,0984,495Research and development (1)

8,1427,59826,76725,534Selling, general and administrative (1)

3,8063,55410,89211,588Total operating expenses

12,80713,98640,75741,617Loss from operations

(4,691)(5,608)(17,662)(22,035)Other income (expense):Interest and other income

4682105367Interest and other expense

(2)(9)(25)(31)Net other income 447380336Net loss$
(21,699)Net loss per share, basic and diluted


Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
2. DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference
3. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
4. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
5. DURECT to Present at the Jefferies Global Life Sciences Conference
6. DURECT to Present at the Rodman & Renshaw Global Healthcare Conference
7. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
8. DURECT to Present at the Barclays Capital Global Healthcare Conference
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
11. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
Post Your Comments:
(Date:8/29/2014)... 2014 The Competitive Intelligence (CI) function is ... CI leaders who adjust will succeed, and those who ... Best Practices, LLC study CI leaders from 32 biopharmaceutical ... - Use secondary research whenever possible - it,s ... - Internal staff who are creative thinkers provide the ...
(Date:8/29/2014)... -- Pomerantz LLP has filed a class action lawsuit ... EDAP ) and certain of its officers.  The ... District of New York , and ... consisting of all persons or entities who purchased EDAP ... inclusive (the "Class Period"). This class action seeks to recover ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... announced the initiation of a landmark Phase 2 ... developed to improve neurological function in patients with ... In accordance with its internal focus on scientific ... at a peer-attended symposium at the American Spinal ...
... April 23, 2012 Medela convened the 7th ... on April 20-21, 2012. The annual event, attended ... lactation consultants, highlighted the latest insights into breastfeeding ... supporting breastfeeding women and their families through research ...
Cached Medicine Technology:Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 2Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 3Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 2Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 3
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Village, IL (PRWEB) August 29, 2014 ... in hearing wellness solutions, is on its way to ... at the San Diego Convention Center to exhibit and ... who work in high-noise industrial environments. Etymotic’s safety earphones ... hottest wearable technology devices at the show. , ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 ... “The Safety Chick” who profiled a handful of ... Earphones from Etymotic Research. This year, many schools ... and Etymotic, an innovator of hearing wellness solutions, ... Their ETY•Kids Safe-Listening Earphones, offered in yellow, pink ...
(Date:8/29/2014)... London, UK (PRWEB) August 29, 2014 ... growing ones in the in-vitro diagnostics industry; it is ... The growth is driven by the ongoing spread of ... a primary factor associated with the upsurge of opportunistic ... diagnostic; and a broader availability of immunosuppressive medicines. Although ...
(Date:8/29/2014)... Edvance360, a leading provider of eLearning ... teaching, as well as 2011 winner and six-time-finalist for ... System, announced that Brooke Education Services, Northwest Academy, Typewell, ... Advertising Bureau of Canada (IAB Canada), StarSVCS, and HMG ... delighted to welcome each new client to the growing ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at 3Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2
... price for a 30-second advertising spot in the 2012 Super Bowl ... study suggests that, for advertisers, it may not really matter if ... But for the sake of companies forking out big bucks on ... The study by an Oregon State University researcher, which is ...
... -- Teens who think of themselves as thrill-seekers and who ... likely to drive with other teens in the car, which ... finds. And a second study of teens involved in ... distraction and risky driving behavior often played a role. ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) -- ... provide insight into whether patients are at high risk of ... cancer. The test, which is currently available, could ... prevent the cancer from returning. There are caveats: The ...
... a "common sense" decision to start the company in a ... belt. , "We wanted to give better stroke care," said ... of Neurology at the Medical College of Georgia at Georgia ... and his colleagues were frustrated that nearly five years after ...
... By Denise Mann HealthDay Reporter , THURSDAY, Jan. ... for liver cancer among people with hepatitis B, a new study ... hepatitis B virus, is one of the main causes of liver ... have shown promise in reducing risk for cancer. Other studies have ...
... a sensitive non-invasive marker of early lung disease in young ... from Australian researchers. "We found that LCI is elevated ... airway inflammation and Pseudomonas aeruginosa," said Yvonne Belessis, MBBS, MPH, ... may not only be a marker of early CF lung ...
Cached Medicine News:Health News:Sporting event ads viewed favorably - especially if the game is close 2Health News:Teen Driver's Friends Can Be Dangerous Distraction, Studies Find 2Health News:Test Might Predict Risk of Lung Cancer's Return 2Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... To help cardiologists meet the ... Toshiba introduces the high performance Infinix ... solutions combine easy-to-use controls, one-touch operations, ... to optimize workflow and allow physicians ...
Cardiac 5-Axis Bi-plane: Infinix CF-i/BP...
... on the promise of Flat Panel ... outstanding image quality, at lower doses, ... small devices and structures. The new ... at lower dose than other systems ...
Medicine Products: